With annual revenues of greater than $100 million, Paratek is one of the largest independent antibiotics companies in the world. Its lead commercial product, NUZYRA® (omadacycline), is a once-daily oral and intravenous antibiotic available in the United States for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). NUZYRA is the first-choice antibiotic for patients with comorbidities or suspected resistant pathogens. Paratek’s specialty pharmaceutical platform enables both the development and commercialisation of new drugs to bring new innovative therapies to patients.